BioCentury
ARTICLE | Product Development

Roche reveals trial failures

April 23, 2020 1:31 AM UTC

Along with its 1Q20 earnings, Roche disclosed negative readouts in three clinical trials.

Following a futility analysis, Roche (SIX:ROG; OTCQX:RHHBY) stopped the Phase III V1aduct trial of V1a receptor antagonist balovaptan (RG7314) to treat adults with autism; a Phase II pediatric study is ongoing. ...